Retraction: A comprehensive review on metabolic syndrome (Cardiology Research and Practice (2014) 2014 (943162) DOI: 10.1155/2014/943162);A comprehensive review on metabolic syndrome

Cardiology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Kaur, Jaspinder ^a  

^a Ex Servicemen Contributory Health Scheme (ECHS) Polyclinic   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; METFORMIN; NICOTINIC ACID; PHENTERMINE; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ABDOMINAL OBESITY; BARIATRIC SURGERY; BEHAVIOR THERAPY; BODY MASS; CHRONIC STRESS; DYSLIPIDEMIA; EXERCISE; FAT INTAKE; FLATULENCE; FLUSHING; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBID OBESITY; MORNING DOSAGE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; STEATORRHEA; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

EID: 84897522177     PISSN: 20908016     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2019/4301528     Document Type: Erratum

References (221)

1. Alberti K. G. M. M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J.-C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation 2009 120 16 1640 1645 2-s2.0-70350245011 10.1161/CIRCULATIONAHA.109.192644
2. Alberti K. G. M. M., Zimmet P., The metabolic syndrome-a new worldwide definition. The Lancet 2005 366 9491 1059 1062 2-s2.0-25144459980 10.1016/S0140-6736(05)67402-8 (Pubitemid 41338752)
3. Olijhoek J. K., Van Der Graaf Y., Banga J.-D., Algra A., Rabelink T. J., Visseren F. L. J., The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. European Heart Journal 2004 25 4 342 348 2-s2.0-1542286084 10.1016/j.ehj.2003.12.007 (Pubitemid 38295444)
4. Grundy S. M., Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology 2006 47 6 1093 1100 2-s2.0-33644898538 10.1016/j.jacc.2005.11.046
5. Alberti K. G., Zimmet P. Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998 15 7 539 553 (Pubitemid 28319935)
6. Balkau B., Charles M. A., Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine 1999 16 5 442 443 2-s2.0-0032709705 10.1046/j.1464-5491.1999. 00059.x
7. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696 (Pubitemid 32433843)
8. Einhorn D., Reaven G. M., Cobin R. H., Ford E., Ganda O. P., Handelsman Y., Hellman R., Jellinger P. S., Kendall D., Krauss R. M., Neufeld N. D., Petak S. M., Rodbard H. W., Seibel J. A., Smith D. A., Wilson P. W. F., American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine Practice 2003 9 3 237 252 2-s2.0-0347853481
9. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, http://www.idf.org/metabolic-syndrome
10. Shaw J. E., Alberti K. G. M. M., Point: impaired fasting glucose: the case for the new American Diabetes Association criterion. Diabetes Care 2006 29 5 1170 1172 2-s2.0-33746357913 10.2337/diacare.2951170 (Pubitemid 44115266)
11. Shaw J. E., Chisholm D. J., Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Medical Journal of Australia 2003 179 7 379 383 2-s2.0-0142062917 (Pubitemid 37265135)
12. Kylin E., Studien ueber das Hypertonie-Hyperglyca "mie- Hyperurika" miesyndrom. Zentralblatt fuer Innere Medizin 1923 44 105 127
13. Vague J., Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale 1947 30 S39 S40
14. Avogaro P., Crepaldi G., Essential hyperlipidemia, obesity and diabetes. Diabetologia 1965 1 137
15. Reaven G. M., Role of insulin resistance in human disease. Diabetes 1988 37 12 1595 1607 2-s2.0-0024160877 (Pubitemid 19004941)
16. Kaplan N. M., The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine 1989 149 7 1514 1520 2-s2.0-0024391834 (Pubitemid 19177621)
17. Haffner S. M., Valdez R. A., Hazuda H. P., Mitchell B. D., Morales P. A., Stern M. P., Prospective analysis of the insulin-resistance syndrome (Syndrome X). Diabetes 1992 41 6 715 722 2-s2.0-0026762721
18. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. The Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
19. Ford E. S., Prevalence of the metabolic syndrome in US populations. Endocrinology and Metabolism Clinics of North America 2004 33 2 333 350 2-s2.0-2542465083 10.1016/j.ecl.2004.03.004 (Pubitemid 38680633)
20. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C. Jr., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
21. Wilson P. W. F., D'Agostino R. B., Parise H., Sullivan L., Meigs J. B., Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005 112 20 3066 3072 2-s2.0-30944451953 10.1161/CIRCULATIONAHA.105.539528 (Pubitemid 43113437)
22. Ritchie S. A., Connell J. M. C., The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 2007 17 4 319 326 2-s2.0-34047266814 10.1016/j.numecd.2006.07.005 (Pubitemid 46551691)
23. Desroches S., Lamarche B., The evolving definitions and increasing prevalence of the metabolic syndrome. Applied Physiology, Nutrition and Metabolism 2007 32 1 23 32 2-s2.0-34047229523 10.1139/H06-095
24. Kolovou G. D., Anagnostopoulou K. K., Salpea K. D., Mikhailidis D. P., The prevalence of metabolic syndrome in various populations. The American Journal of the Medical Sciences 2007 333 6 362 371 2-s2.0-34250645781 10.1097/MAJ.0b013e318065c3a1 (Pubitemid 46945477)
25. Cameron A. J., Shaw J. E., Zimmet P. Z., The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America 2004 33 2 351 375 10.1016/j.ecl.2004.03.005 (Pubitemid 38680634)
26. Park Y.-W., Zhu S., Palaniappan L., Heshka S., Carnethon M. R., Heymsfield S. B., The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine 2003 163 4 427 436 2-s2.0-0037463608 10.1001/archinte.163.4.427 (Pubitemid 36241019)
27. Ford E. S., Giles W. H., Dietz W. H., Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association 2002 287 3 356 359 2-s2.0-0037116641 (Pubitemid 34251969)
28. Ponholzer A., Temml C., Rauchenwald M., Marszalek M., Madersbacher S., Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women? International Journal of Impotence Research 2008 20 1 100 104 2-s2.0-38149062672 10.1038/sj.ijir.3901605
29. Wilson P. W. F., Kannel W. B., Silbershatz H., D'Agostino R. B., Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine 1999 159 10 1104 1109 2-s2.0-0033599981 10.1001/archinte.159.10.1104 (Pubitemid 29230863)
30. Palaniappan L., Carnethon M. R., Wang Y., Hanley A. J. G., Fortmann S. P., Haffner S. M., Wagenknecht L., Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004 27 3 788 793 2-s2.0-1442275319 10.2337/diacare.27.3.788 (Pubitemid 38280551)
31. Reilly M. P., Rader D. J., The metabolic syndrome: more than the sum of its parts? Circulation 2003 108 13 1546 1551 2-s2.0-0141730248 10.1161/01.CIR.0000088846.10655.E0 (Pubitemid 37187778)
32. Andreadis E. A., Tsourous G. I., Tzavara C. K., Georgiopoulos D. X., Katsanou P. M., Marakomichelakis G. E., Diamantopoulos E. J., Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. The American Journal of Hypertension 2007 20 5 558 564 2-s2.0-34247626807 10.1016/j.amjhyper.2006.12.001 (Pubitemid 46678707)
33. Halberg N., Wernstedt-Asterholm I., Scherer P. E., The adipocyte as an endocrine cell. Endocrinology and Metabolism Clinics of North America 2008 37 3 753 768 2-s2.0-50449100949 10.1016/j.ecl.2008.07.002
34. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., Wang S., Fortier M., Greenberg A. S., Obin M. S., Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research 2005 46 11 2347 2355 2-s2.0-27444437321 10.1194/jlr.M500294-JLR200 (Pubitemid 41532523)
35. Lau D. C. W., Dhillon B., Yan H., Szmitko P. E., Verma S., Adipokines: molecular links between obesity and atheroslcerosis. The American Journal of Physiology-Heart and Circulatory Physiology 2005 288 5 H2031 H2041 2-s2.0-18044366410 10.1152/ajpheart.01058.2004 (Pubitemid 40604084)
36. Trayhurn P., Wood I. S., Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 2004 92 3 347 355 2-s2.0-6944237757 10.1079/BJN20041213 (Pubitemid 40277057)
37. Saleem U., Khaleghi M., Morgenthaler N. G., Bergmann A., Struck J., Mosley T. H. Jr., Kullo I. J., Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 7 2558 2564 2-s2.0-67650257679 10.1210/jc.2008-2278
38. Tsimikas S., Willeit J., Knoflach M., Mayr M., Egger G., Notdurfter M., Witztum J. L., Wiedermann C. J., Xu Q., Kiechl S., Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. European Heart Journal 2009 30 1 107 115 2-s2.0-58149157445 10.1093/eurheartj/ehn502
39. Jacobs M., Van Greevenbroek M. M. J., Van Der Kallen C. J. H., Ferreira I., Blaak E. E., Feskens E. J. M., Jansen E. H. J. M., Schalkwijk C. G., Stehouwer C. D. A., Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. European Journal of Clinical Investigation 2009 39 6 437 444 2-s2.0-65549153242 10.1111/j.1365-2362.2009. 02129.x
40. Miles J. M., Jensen M. D., Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005 28 9 2326 2328 2-s2.0-24144473122 10.2337/diacare.28.9.2326 (Pubitemid 41242491)
41. Boden G., Lebed B., Schatz M., Homko C., Lemieux S., Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001 50 7 1612 1617 2-s2.0-0035405847 (Pubitemid 33639602)
42. Kahn S. E., Prigeon R. L., Schwartz R. S., Fujimoto W. Y., Knopp R. H., Brunzell J. D., Porte D. Jr., Obesity, body fat distribution, insulin sensitivity and islet β -cell function as explanations for metabolic diversity. Journal of Nutrition 2001 131 2 354S 360S 2-s2.0-0035156262 (Pubitemid 32115380)
43. Xydakis A. M., Case C. C., Jones P. H., Hoogeveen R. C., Liu M.-Y., O'Brian Smith E., Nelson K. W., Ballantyne C. M., Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight lose through caloric restriction. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2697 2703 2-s2.0-2942677231 10.1210/jc.2003-031826 (Pubitemid 38766352)
44. Hotamisligil G. S., Peraldi P., Budavari A., Ellis R., White M. F., Spiegelman B. M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α-and obesity-induced insulin resistance. Science 1996 271 5249 665 668 2-s2.0-0030061922 (Pubitemid 26052915)
45. Krauss R. M., Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004 27 6 1496 1504 2-s2.0-2542492541 10.2337/diacare.27.6.1496 (Pubitemid 38680002)
46. Soto González A., Bellido Guerrero D., Buño Soto M., Pértega Díaz S., Martinez-Olmos M., Vidal O., Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. European Journal of Clinical Nutrition 2006 60 6 802 809 2-s2.0-33744927645 10.1038/sj.ejcn.1602384 (Pubitemid 43842236)
47. Deepa R., Velmurugan K., Arvind K., Sivaram P., Sientay C., Uday S., Mohan V., Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006 55 9 1232 1238 2-s2.0-33747067941 10.1016/j.metabol. 2006.05.008 (Pubitemid 44215943)
48. Guldiken S., Demir M., Arikan E., Turgut B., Azcan S., Gerenli M., Tugrul A., The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thrombosis Research 2007 119 1 79 84 2-s2.0-33750840076 10.1016/j.thromres.2005.12.019 (Pubitemid 44716209)
49. McLaughlin T., Abbasi F., Lamendola C., Liang L., Reaven G., Schaaf P., Reaven P., Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002 106 23 2908 2912 2-s2.0-0037016001 10.1161/01.CIR.0000041046.32962.86 (Pubitemid 35424740)
50. Ridker P. M., Buring J. E., Cook N. R., Rifai N., C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 107 3 391 397 2-s2.0-0037469255
51. Clearfield M. B., C-reactive protein: a new risk assessment tool for cardiovascular disease. Journal of the American Osteopathic Association 2005 105 9 409 416 2-s2.0-27744607652 (Pubitemid 41603444)
52. Pedersen B. K., Steensberg A., Fischer C., Keller C., Keller P., Plomgaard P., Febbraio M., Saltin B., Searching for the exercise factor: is IL-6 a candidate? Journal of Muscle Research and Cell Motility 2003 24 2-3 113 119 2-s2.0-0142187317 10.1023/A:1026070911202 (Pubitemid 37323614)
53. Stenlöf K., Wernstedt I., Fjällman T., Wallenius V., Wallenius K., Jansson J.-O., Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 9 4379 4383 2-s2.0-0141675985 10.1210/jc.2002-021733 (Pubitemid 37153746)
54. Diamant M., Lamb H. J., Van De Ree M. A., Endert E. L., Groeneveld Y., Bots M. L., Kostense P. J., Radder J. K., The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1495 1501 2-s2.0-15944371339 10.1210/jc.2004-1579 (Pubitemid 40464010)
55. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
56. Zuliani G., Volpato S., Blè A., Bandinelli S., Corsi A. M., Lauretani F., Paolisso G., Fellin R., Ferrucci L., High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis 2007 192 2 384 390 2-s2.0-34248358258 10.1016/j.atherosclerosis.2006.05.024 (Pubitemid 46735937)
57. Alessi M.-C., Juhan-Vague I., PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 10 2200 2207 2-s2.0-33749052752 10.1161/01.ATV.0000242905.41404.68 (Pubitemid 44465712)
58. Cigolini M., Targher G., Andreis I. A. B., Tonoli M., Agostino G., De Sandre G., Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 3 368 374 2-s2.0-0029983028 (Pubitemid 26084311)
59. Alessi M. C., Juhan-Vague I., Contribution of PAI-1 in cardiovascular pathology. Archives des Maladies du Coeur et des Vaisseaux 2004 97 6 673 678 2-s2.0-3042584530 (Pubitemid 38843352)
60. Kohler H. P., Grant P. J., Plasminogen-activator inhibitor type 1 and coronary artery disease. The New England Journal of Medicine 2000 342 24 1792 1801 2-s2.0-0034660437 10.1056/NEJM200006153422406 (Pubitemid 30390240)
61. Liu M., Liu F., Transcriptional and post-translational regulation of adiponectin. Biochemical Journal 2010 425 1 41 52 2-s2.0-72449141637 10.1042/BJ20091045
62. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I., Adiponectin and metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 1 29 33 2-s2.0-0345861775 10.1161/01.ATV.0000099786.99623.EF (Pubitemid 38082408)
63. Kazumi T., Kawaguchi A., Sakai K., Hirano T., Yoshino G., Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002 25 6 971 976 2-s2.0-0036598335 10.2337/diacare.25.6.971 (Pubitemid 41110480)
64. Pischon T., Girman C. J., Hotamisligil G. S., Rifai N., Hu F. B., Rimm E. B., Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association 2004 291 14 1730 1737 2-s2.0-1842864234 10.1001/jama.291.14.1730 (Pubitemid 38489895)
65. Fumeron F., Aubert R., Siddiq A., Betoulle D., Péan F., Hadjadj S., Tichet J., Wilpart E., Chesnier M.-C., Balkau B., Froguel P., Marre M., Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 2004 53 4 1150 1157 2-s2.0-12144291012 10.2337/diabetes.53.4.1150 (Pubitemid 38436631)
66. Lee H.-S., Lee M., Joung H., Adiponectin represents an independent risk factor for hypertension in middle aged Korean women. Asia Pacific Journal of Clinical Nutrition 2007 16 1 10 15 2-s2.0-33847156042 (Pubitemid 46280352)
67. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., Matsuzawa Y., PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001 50 9 2094 2099 2-s2.0-0035462629 (Pubitemid 33643677)
68. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., Paschke R., Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 2003 301 4 1045 1050 2-s2.0-0037459090 10.1016/S0006-291X(03) 00090-1 (Pubitemid 36279218)
69. Engeli S., Feldpausch M., Gorzelniak K., Hartwig F., Heintze U., Janke J., Möhlig M., Pfeiffer A. F. H., Luft F. C., Sharma A. M., Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003 52 4 942 947 2-s2.0-0037380664 10.2337/diabetes.52.4.942 (Pubitemid 36384264)
70. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y., Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF- B signaling through a cAMP-dependent pathway. Circulation 2000 102 11 1296 1301 2-s2.0-0034641647
71. Hutley L., Prins J. B., Fat as an endocrine organ: relationship to the metabolic syndrome. The American Journal of the Medical Sciences 2005 330 6 280 289 2-s2.0-29244465117 (Pubitemid 41831898)
72. Carlyle M., Jones O. B., Kuo J. J., Hall J. E., Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002 39 2 496 501 2-s2.0-0036179086 10.1161/hy0202.104398 (Pubitemid 34165172)
73. Eikelis N., Schlaich M., Aggarwal A., Kaye D., Esler M., Interactions between leptin and the human sympathetic nervous system. Hypertension 2003 41 5 1072 1079 2-s2.0-0038334588 10.1161/01.HYP.0000066289.17754.49 (Pubitemid 36548605)
74. Marsh A. J., Fontes M. A. P., Killinger S., Pawlak D. B., Polson J. W., Dampney R. A. L., Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 2003 42 4 488 493 2-s2.0-0141997258 10.1161/01.HYP.0000090097.22678.0A (Pubitemid 37237343)
75. Shirasaka T., Takasaki M., Kannan H., Cardiovascular effects of leptin and orexins. The American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2003 284 3 R639 R651 2-s2.0-0037343052 (Pubitemid 36342796)
76. Considine R. V., Sinha M. K., Heiman M. L., Kriauciunas A., Stephens T. W., Nyce M. R., Ohannesian J. P., Marco C. C., Mckee L. J., Bauer T. L., Caro J. F., Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England Journal of Medicine 1996 334 5 292 295 2-s2.0-13344295079 10.1056/NEJM199602013340503 (Pubitemid 26033933)
77. Bravata D. M., Wells C. K., Concato J., Kernan W. N., Brass L. M., Gulanski B. I., Two measures of insulin sensitivity provided similar information in a U.S. population. Journal of Clinical Epidemiology 2004 57 11 1214 1217 2-s2.0-9644282994 10.1016/j.jclinepi.2004.05.001 (Pubitemid 39573031)
78. Carey D. G., Jenkins A. B., Campbell L. V., Freund J., Chisholm D. J., Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996 45 5 633 638 2-s2.0-0029874313 (Pubitemid 26140548)
79. Mayer-Davis E. J., D'Agostino R. Jr., Karter A. J., Haffner S. M., Rewers M. J., Saad M., Bergman R. N., Intensity and amount of physical activity in relation to insulin sensitivity the Insulin Resistance Atherosclerosis Study. Journal of the American Medical Association 1998 279 9 669 674 2-s2.0-0032481673 10.1001/jama.279.9.669 (Pubitemid 28138735)
80. Vessby B., Uusitupa M., Hermansen K., Riccardi G., Rivellese A. A., Tapsell L. C., Nälsén C., Berglund L., Louheranta A., Rasmussen B. M., Calvert G. D., Maffetone A., Pedersen E., Gustafsson I.-B., Storlien L. H., Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia 2001 44 3 312 319 2-s2.0-0035081372 10.1007/s001250051620 (Pubitemid 32234457)
81. Gill H., Mugo M., Whaley-Connell A., Stump C., Sowers J. R., The key role of insulin resistance in the cardiometabolic syndrome. The American Journal of the Medical Sciences 2005 330 6 290 294 2-s2.0-29244436880 (Pubitemid 41831899)
82. Petersen K. F., Shulman G. I., Etiology of insulin resistance. The American Journal of Medicine 2006 119 5 S10 S16 2-s2.0-33645074450 10.1016/j.amjmed.2006.01.009
83. Jensen M. D., Haymond M. W., Rizza R. A., Cryer P. E., Miles J. M., Influence of body fat distribution on free fatty acid metabolism in obesity. Journal of Clinical Investigation 1989 83 4 1168 1173 2-s2.0-0024602053 (Pubitemid 19113028)
84. Lewis G. F., Steiner G., Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state. Diabetes Care 1996 19 4 390 393 2-s2.0-0029865259 (Pubitemid 26115468)
85. Ginsberg H. N., Zhang Y.-L., Hernandez-Ono A., Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research 2005 36 3 232 240 2-s2.0-19944366619 10.1016/j.arcmed.2005.01.005 (Pubitemid 40755136)
86. Ferrannini E., Natali A., Essential hypertension, metabolic disorders, and insulin resistance. The American Heart Journal 1991 121 4 1274 1282 2-s2.0-0026029959 10.1016/0002-8703(91)90433-I
87. Malhotra A., Kang B. P. S., Cheung S., Opawumi D., Meggs L. G., Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001 50 8 1918 1926 2-s2.0-0035430525 (Pubitemid 33641614)
88. Morse S. A., Zhang R., Thakur V., Reisin E., Hypertension and the metabolic syndrome. The American Journal of the Medical Sciences 2005 330 6 303 310 2-s2.0-29244456775 (Pubitemid 41831901)
89. Briones A. M., Cat A. N. D., Callera G. E., Yogi A., Burger D., He Y., Corrêa J. W., Gagnon A. M., Gomez-Sanchez C. E., Gomez-Sanchez E. P., Sorisky A., Ooi T. C., Ruzicka M., Burns K. D., Touyz R. M., Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012 59 5 1069 1078 2-s2.0-84860226019 10.1161/HYPERTENSIONAHA.111.190223
90. Ordovas J. M., Genetic links between diabetes mellitus and coronary atherosclerosis. Current Atherosclerosis Reports 2007 9 3 204 210 2-s2.0-35448960854 10.1007/s11883-007-0020-9 (Pubitemid 47629068)
91. Perseghin G., Ghosh S., Gerow K., Shulman G. I., Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997 46 6 1001 1009 2-s2.0-0030941820 (Pubitemid 27221001)
92. Abate N., Chandalia M., Snell P. G., Grundy S. M., Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2750 2755 2-s2.0-2942685611 10.1210/jc.2003-031843 (Pubitemid 38766361)
93. Martin L. J., North K. E., Dyer T., Blangero J., Comuzzie A. G., Williams J., Phenotypic, genetic, and genome-wide structure in the metabolic syndrome. BMC Genetics 2003 4 supplement 1, article S95 10.1186/1471-2156-4-S1-S95
94. Laakso M., Gene variants, insulin resistance, and dyslipidaemia. Current Opinion in Lipidology 2004 15 2 115 120 2-s2.0-1842452946 10.1097/00041433- 200404000-00004 (Pubitemid 38453399)
95. Poulsen P., Levin K., Petersen I., Christensen K., Beck-Nielsen H., Vaag A., Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005 54 1 275 283 2-s2.0-12144273136 10.2337/diabetes.54.1.275 (Pubitemid 40105123)
96. Neel J. V., Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? The American Journal of Human Genetics 1962 14 353 362 2-s2.0-70349566593
97. Hales C. N., Barker D. J. P., Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992 35 7 595 601 2-s2.0-0026772772 10.1007/BF00400248
98. Hales C. N., Desai M., Ozanne S. E., The thrifty phenotype hypothesis: how does it look after 5 years? Diabetic Medicine 1997 14 3 189 195 (Pubitemid 27151830)
99. Locatelli F., Pozzoni P., Del Vecchio L., Renal manifestations in the metabolic syndrome. Journal of the American Society of Nephrology 2006 17 4, supplement 2 S81 S85 2-s2.0-33645468472 10.1681/ASN.2005121332
100. Bruce K. D., Byrne C. D., The metabolic syndrome: common origins of a multifactorial disorder. Postgraduate Medical Journal 2009 85 1009 614 621 2-s2.0-73249128357 10.1136/pgmj.2008.078014
101. Padhi T., Garima, Metabolic syndrome and skin: psoriasis and beyond. Indian Journal of Dermatology 2013 58 3 299 305 10.4103/0019-5154.113950
102. Chopra R., Chander A., Jacob J. J., Ocular associations of metabolic syndrome. Indian Journal of Endocrinology and Metabolism 2012 16 supplement 1 S6 S11
103. Lam J. C. M., Mary S. M. I., Sleep & the metabolic syndrome. Indian Journal of Medical Research 2010 131 2 206 216 2-s2.0-77649297298
104. Dokras A., Bochner M., Hollinrake E., Markham S., Van Voorhis B., Jagasia D. H., Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics and Gynecology 2005 106 1 131 137 2-s2.0-21244477098 (Pubitemid 40898445)
105. Standl E., Aetiology and consequences of the metabolic syndrome. European Heart Journal, Supplement 2005 7 supplement D D10 D13 2-s2.0-20744439397 10.1093/eurheartj/sui023 (Pubitemid 40853039)
106. Handelsman Y., Metabolic syndrome pathophysiology and clinical presentation. Toxicologic Pathology 2009 37 1 18 20 2-s2.0-62749204395 10.1177/0192623308329288
107. Kraemer-Aguiar L. G., Laflor C. M., Bouskela E., Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 2008 57 12 1740 1746 2-s2.0-55649114163 10.1016/j.metabol.2008.07.034
108. Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005 352 16 1685 1695 2-s2.0-17644412023 10.1056/NEJMra043430 (Pubitemid 40530235)
109. Harrison D. G., Cellular and molecular mechanisms of endothelial cell dysfunction. Journal of Clinical Investigation 1997 100 9 2153 2157 2-s2.0-0030711684 (Pubitemid 27500136)
110. Grundy S. M., Obesity, metabolic syndrome, and cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2595 2600 2-s2.0-2942675088 10.1210/jc.2004-0372 (Pubitemid 38766337)
111. Aljada A., Mohanty P., Ghanim H., Abdo T., Tripathy D., Chaudhuri A., Dandona P., Increase in intranuclear nuclear factor B and decrease in inhibitor B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. The American Journal of Clinical Nutrition 2004 79 4 682 690 2-s2.0-2142827887 (Pubitemid 41103915)
112. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R., Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005 111 11 1448 1454 2-s2.0-15444366991 10.1161/01.CIR.0000158483.13093.9D (Pubitemid 40396812)
113. Charmandari E., Tsigos C., Chrousos G., Endocrinology of the stress response. Annual Review of Physiology 2005 67 259 284 2-s2.0-15544368594 10.1146/annurev.physiol.67.040403.120816 (Pubitemid 40409509)
114. Wang C.-N., McLeod R. S., Yao Z., Brindley D. N., Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 9 1481 1491 2-s2.0-0029121196
115. Argaud D., Zhang Q., Pan W., Maitra S., Pilkis S. J., Lange A. J., Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5′-flanking sequence. Diabetes 1996 45 11 1563 1571 2-s2.0-0029958181 (Pubitemid 26357550)
116. Hauner H., Entenmann G., Wabitsch M., Gaillard D., Ailhaud G., Negrel R., Pfeiffer E. F., Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. Journal of Clinical Investigation 1989 84 5 1663 1670 2-s2.0-0024440502 (Pubitemid 19272257)
117. Grunfeld C., Jones D. S., Glucocorticoid-induced insulin resistance in vitro: inhibition of insulin-stimulated methylaminoisobutyric acid uptake. Hormone and Metabolic Research 1986 18 3 149 152 2-s2.0-0022592957 (Pubitemid 16122212)
118. Guillaume-Gentil C., Assimacopoulos-Jeannet F., Jeanrenaud B., Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 1993 36 10 899 906 2-s2.0-0027421710 (Pubitemid 23288748)
119. Andrew R., Gale C. R., Walker B. R., Seckl J. R., Martyn C. N., Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Experimental and Clinical Endocrinology and Diabetes 2002 110 6 284 290 2-s2.0-0036710815 10.1055/s-2002-34591 (Pubitemid 35246745)
120. Chrousos G. P., Stress and disorders of the stress system. Nature Reviews Endocrinology 2009 5 7 374 381 2-s2.0-69449108280 10.1038/nrendo.2009.106
121. Wong N. D., Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Preventive Cardiology 2005 8 1 47 54 2-s2.0-17844371317
122. Deen D., Metabolic syndrome: time for action. The American Family Physician 2004 69 12 2875 2887 2-s2.0-3042700220
123. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation 2002 106 25 3143 3421
124. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L. Jr., Jones D. W., Materson B. J., Oparil S., Wright J. T. Jr., Roccella E. J., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Journal of the American Medical Association 2003 289 19 2560 2572 2-s2.0-0038460302 10.1001/jama.289.19.2560 (Pubitemid 37430158)
125. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care 2005 28 supplement 1 S1 79
126. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. National Institutes of Health. Obesity Research 1998 6 supplement 2 51S 209S
127. Bellentani S., Grave R. D., Suppini A., Marchesini G., Bedogni G., Bugianesi E., Crocè L. S., Gastaldelli A., Marra F., Perseghin G., Svegliati-Baroni G., Tell G., Tiribelli C., Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008 47 2 746 754 2-s2.0-39549092421 10.1002/hep.22009 (Pubitemid 351280743)
128. Donato K. A., Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine 1998 158 17 1855 1867 2-s2.0-0032575852 10.1001/archinte.158.17.1855 (Pubitemid 28440858)
129. Duncan G. E., Perri M. G., Theriaque D. W., Hutson A. D., Eckel R. H., Stacpoole P. W., Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 2003 26 3 557 562 2-s2.0-0042093749 10.2337/diacare.26.3. 557 (Pubitemid 36929307)
130. Van Gaal L. F., Wauters M. A., De Leeuw I. H., The beneficial effects of modest weight loss on cardiovascular risk factors. International Journal of Obesity 1997 21 supplement 1 S5 S9 2-s2.0-0030934629 (Pubitemid 27160691)
131. Whelton P. K., Appel L. J., Espeland M. A., Applegate W. B., Ettinger W. H. Jr., Kostis J. B., Kumanyika S., Lacy C. R., Johnson K. C., Folmar S., Cutler J. A., Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. Journal of the American Medical Association 1998 279 11 839 846 2-s2.0-0032542709 10.1001/jama.279.11.839 (Pubitemid 28185548)
132. Wing R. R., Koeske R., Epstein L. H., Nowalk M. P., Gooding W., Becker D., Long-term effects of modest weight loss in type II diabetic patients. Archives of Internal Medicine 1987 147 10 1749 1753 2-s2.0-0023634861 (Pubitemid 17159673)
133. Ross R., Janssen I., Dawson J., Kungl A.-M., Kuk J. L., Wong S. L., Nguyen-Duy T.-B., Lee S., Kilpatrick K., Hudson R., Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obesity Research 2004 12 5 789 798 2-s2.0-4644229516 (Pubitemid 41127314)
134. Hill J. O., Wyatt H. R., Role of physical activity in preventing and treating obesity. Journal of Applied Physiology 2005 99 2 765 770 2-s2.0-23044496860 10.1152/japplphysiol.00137.2005 (Pubitemid 41061176)
135. Haslam D. W., James W. P. T., Obesity. The Lancet 2005 366 9492 1197 1209 2-s2.0-25844457693 10.1016/S0140-6736(05)67483-1 (Pubitemid 41393598)
136. Toumilheto J., Lindstrom J., Eriksson J. G., Prevention of type 2 diabetes mellitus with lifestyle intervention or metformin. The New England Journal of Medicine 2001 344 18 1343 1350 10.1056/NEJM200105033441801 (Pubitemid 32378388)
137. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002 346 6 393 403 2-s2.0-0037034257 10.1056/NEJMoa012512 (Pubitemid 34437694)
138. Tortosa A., Bes-Rastrollo M., Sanchez-Villegas A., Basterra-Gortari F. J., Nũnez-Cordoba J. M., Martinez-Gonzalez M. A., Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care 2007 30 11 2957 2959 2-s2.0-36048986007 10.2337/dc07-1231 (Pubitemid 350083151)
139. Landaeta-Diaz L., Fernandez J. M., Da Silva-Grigoletto M., Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome. European Journal of Preventive Cardiology 2013 20 4 555 564 10.1177/2047487312445000
140. Paletas K., Athanasiadou E., Sarigianni M., Paschos P., Kalogirou A., Hassapidou M., Tsapas A., The protective role of the mediterranean diet on the prevalence of metabolic syndrome in a population of greek obese subjects. Journal of the American College of Nutrition 2010 29 1 41 45 2-s2.0-77956491850
141. Babio N., Bulló M., Basora J., Martínez-González M. A., Fernández-Ballart J., Márquez-Sandoval F., Molina C., Salas-Salvadó J., Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. Nutrition, Metabolism and Cardiovascular Diseases 2009 19 8 563 570 2-s2.0-61649116490 10.1016/j.numecd.2008.10.007
142. Lien L. F., Brown A. J., Ard J. D., Loria C., Erlinger T. P., Feldstein A. C., Lin P.-H., Champagne C. M., King A. C., McGuire H. L., Stevens V. J., Brantley P. J., Harsha D. W., McBurnie M. A., Appel L. J., Svetkey L. P., Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007 50 4 609 616 2-s2.0-34548841938 10.1161/HYPERTENSIONAHA.107.089458 (Pubitemid 47442722)
143. Garg A., Bantle J. P., Henry R. R., Coulston A. M., Griver K. A., Raatz S. K., Brinkley L., Chen Y.-D. I., Grundy S. M., Huet B. A., Reaven G. M., Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. Journal of the American Medical Association 1994 271 18 1421 1428 2-s2.0-0028211087 10.1001/jama.271.18.1421 (Pubitemid 24132489)
144. Mitch W. E., Beneficial responses to modified diets in treating patients with chronic kidney disease. Kidney International, Supplement 2005 67 94 S133 S135 2-s2.0-15944394343
145. Fabricatore A. N., Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? Journal of the American Dietetic Association 2007 107 1 92 99 2-s2.0-33845738281 10.1016/j.jada.2006.10.005 (Pubitemid 46013809)
146. Wing R. R., Jeffery R. W., Burton L. R., Thorson C., Nissinoff K. S., Baxter J. E., Food provision vs structured meal plans in the behavioral treatment of obesity. International Journal of Obesity 1996 20 1 56 62 2-s2.0-0030064780 (Pubitemid 26025049)
147. Wadden T. A., Butryn M. L., Byrne K. J., Efficacy of lifestyle modification for long-term weight control. Obesity Research 2004 12 S12 151S 162S 2-s2.0-15544371999
148. Johnson A. G., Nguyen T. V., Davis D., Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. Journal of Hypertension 2001 19 6 1053 1060 2-s2.0-0035008185 10.1097/00004872-200106000-00009 (Pubitemid 32493638)
149. He J., Ogden L. G., Vupputuri S., Bazzano L. A., Loria C., Whelton P. K., Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. Journal of the American Medical Association 1999 282 21 2027 2034 2-s2.0-0033485509 10.1001/jama.282.21.2027
150. He J., Ogden L. G., Bazzano L. A., Vupputuri S., Loria C., Whelton P. K., Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first national health and nutrition examination survey epidemiologic follow-up study. Archives of Internal Medicine 2002 162 14 1619 1624 2-s2.0-0037158160 10.1001/archinte.162.14.1619 (Pubitemid 34765011)
151. Appel L. J., Brands M. W., Daniels S. R., Karanja N., Elmer P. J., Sacks F. M., Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006 47 2 296 308 2-s2.0-31944448854 10.1161/01.HYP.0000202568.01167.B6 (Pubitemid 43189776)
152. Whelton P. K., He J., Cutler J. A., Brancati F. L., Appel L. J., Follmann D., Klag M. J., Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. Journal of the American Medical Association 1997 277 20 1624 1632 2-s2.0-0030956083 (Pubitemid 27231195)
153. American Diabetes Association, Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002 25 1 202 212 10.2337/diacare.25.1.202
154. Jenkins D. J. A., Kendall C. W. C., Augustin L. S. A., Franceschi S., Hamidi M., Marchie A., Jenkins A. L., Axelsen M., Glycemic index: overview of implications in health and disease. The American Journal of Clinical Nutrition 2002 76 1 266S 273S 2-s2.0-0036297801 (Pubitemid 34686579)
155. McKeown N. M., Meigs J. B., Liu S., Saltzman E., Wilson P. W. F., Jacques P. F., Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004 27 2 538 546 2-s2.0-0842333082 10.2337/diacare.27.2.538 (Pubitemid 38174084)
156. Thompson P. D., Buchner D., Piña I. L., Balady G. J., Williams M. A., Marcus B. H., Berra K., Blair S. N., Costa F., Franklin B., Fletcher G. F., Gordon N. F., Pate R. R., Rodriguez B. L., Yancey A. K., Wenger N. K., Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation 2003 107 24 3109 3116 2-s2.0-0038677039 10.1161/01.CIR.0000075572.40158.77 (Pubitemid 36758987)
157. Grundy S. M., Hansen B., Smith S. C. Jr., Cleeman J. I., Kahn R. A., American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004 109 4 551 556 2-s2.0-0842285784 10.1161/01.CIR.0000112379. 88385.67 (Pubitemid 38168522)
158. Pollock M. L., Franklin B. A., Balady G. J., Chaitman B. L., Fleg J. L., Fletcher B., Limacher M., Pina I. L., Stein R. A., Williams M., Bazzarre T., Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000 101 7 828 833 2-s2.0-0034700944 (Pubitemid 30100093)
159. The Diabetes Prevention Program Research Group, The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002 25 12 2165 2171 10.2337/diacare.25.12.2165 (Pubitemid 41071022)
160. Haskell W. L., Lee I.-M., Pate R. R., Powell K. E., Blair S. N., Franklin B. A., Macera C. A., Heath G. W., Thompson P. D., Bauman A., Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007 116 9 1081 1093 2-s2.0-34548222136 10.1161/CIRCULATIONAHA.107.185649 (Pubitemid 47329572)
161. Goodpaster B. H., He J., Watkins S., Kelley D. E., Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. Journal of Clinical Endocrinology and Metabolism 2001 86 12 5755 5761 2-s2.0-0035217707 10.1210/jc.86.12.5755 (Pubitemid 33152620)
162. Slentz C. A., Duscha B. D., Johnson J. L., Ketchum K., Aiken L. B., Samsa G. P., Houmard J. A., Bales C. W., Kraus W. E., Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE-a randomized controlled study. Archives of Internal Medicine 2004 164 1 31 39 2-s2.0-0347319214 10.1001/archinte.164.1.31 (Pubitemid 38067386)
163. Pate R. R., Pratt M., Blair S. N., Haskell W. L., Macera C. A., Bouchard C., Buchner D., Ettinger W., Heath G. W., King A. C., Kriska A., Leon A. S., Marcus B. H., Morris J., Paffenbarger R. S. Jr., Patrick K., Pollock M. L., Rippe J. M., Sallis J., Wilmore J. H., Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. Journal of the American Medical Association 1995 273 5 402 407 2-s2.0-0028814439
164. Ford E. S., Kohl H. W. III, Mokdad A. H., Ajani U. A., Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obesity Research 2005 13 3 608 614 2-s2.0-22844436649
165. Koplan J. P., Dietz W. H., Caloric imbalance and public health policy. Journal of the American Medical Association 1999 282 16 1579 1581 2-s2.0-0032718020 10.1001/jama.282.16.1579 (Pubitemid 29504052)
166. Wing R. R., Wadden T. A., Stunkard A. J., Behavioral weight control. Handbook of Obesity Treatment 2002 New York, NY, USA Guildford Press 301 316
167. Wadden T. A., McGuckin B. G., Rothman R. A., Sargent S. L., Lifestyle modification in the management of obesity. Journal of Gastrointestinal Surgery 2003 7 4 452 463 2-s2.0-0037962226 10.1016/S1091-255X(03)00048-9 (Pubitemid 36877182)
168. Ferrari C. K. B., Functional foods and physical activities in health promotion of aging people. Maturitas 2007 58 4 327 339 2-s2.0-36448932371 10.1016/j.maturitas.2007.09.011 (Pubitemid 350167511)
169. Wilson P. W. F., Grundy S. M., The metabolic syndrome practical guide to origins and treatment: part I. Circulation 2003 108 12 1422 1424 2-s2.0-0141504302 10.1161/01.CIR.0000089505.34741.E5 (Pubitemid 37176444)
170. Krejs G. J., Metabolic benefits associated with sibutramine therapy. International Journal of Obesity 2002 26 supplement 4 S34 S37 2-s2.0-0036945863 10.1038/sj.ijo.0802217 (Pubitemid 36071970)
171. Miles J. M., Leiter L., Hollander P., Wadden T., Anderson J. W., Doyle M., Foreyt J., Aronne L., Klein S., Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 25 7 1123 1128 2-s2.0-0036634125 10.2337/diacare.25.7.1123 (Pubitemid 41071161)
172. Haddock C. K., Poston W. S. C., Dill P. L., Foreyt J. P., Ericsson M., Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity 2002 26 2 262 273 2-s2.0-0036178685 10.1038/sj/ijo/0801889 (Pubitemid 34151206)
173. Grundy S. M., Cleeman J. I., Bairey Merz C. N., Brewer H. B. Jr., Clark L. T., Hunninghake D. B., Pasternak R. C., Smith S. C. Jr., Stone N. J., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 2 227 239 2-s2.0-3142729178 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
174. Folli F., Pontiroli A. E., Schwesinger W. H., Metabolic aspects of bariatric surgery. Medical Clinics of North America 2007 91 3 393 414 2-s2.0-34248196458 10.1016/j.mcna.2007.01.005 (Pubitemid 46726487)
175. Sjöström L., Lindroos A.-K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., Dahlgren S., Larsson B., Narbro K., Sjöström C. D., Sullivan M., Wedel H., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine 2004 351 26 2683 2693 2-s2.0-10844295087 10.1056/NEJMoa035622 (Pubitemid 39665322)
176. Wolfe B. M., Morton J. M., Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. Journal of the American Medical Association 2005 294 15 1960 1963 2-s2.0-26844441917 10.1001/jama.294.15.1960 (Pubitemid 41464698)
177. Bakker-Arkema R. G., Davidson M. H., Goldstein R. J., Davignon J., Isaacsohn J. L., Weiss S. R., Keilson L. M., Brown W. V., Miller V. T., Shurzinske L. J., Black D. M., Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of the American Medical Association 1996 275 2 128 133 2-s2.0-9044230921 10.1001/jama.275.2.128 (Pubitemid 26022591)
178. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M. Jr., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association 1998 279 20 1615 1622 2-s2.0-0032572086 10.1001/jama.279.20.1615 (Pubitemid 28248586)
179. Davignon J., Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 23 III39 III43 2-s2.0-2942720515 (Pubitemid 38786442)
180. Bloomgarden Z. T., Obesity, hypertension, and insulin resistance. Diabetes Care 2002 25 11 2088 2097 2-s2.0-0036833815
181. Deedwania P. C., Hunninghake D. B., Bays H. E., Jones P. H., Cain V. A., Blasetto J. W., Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American Journal of Cardiology 2005 95 3 360 366 2-s2.0-12844271249 10.1016/j.amjcard.2004.09.034 (Pubitemid 40164540)
182. Kashyap M. L., McGovern M. E., Berra K., Guyton J. R., Kwiterovich P. O. Jr., Harper W. L., Toth P. D., Favrot L. K., Kerzner B., Nash S. D., Bays H. E., Simmons P. D., Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. The American Journal of Cardiology 2002 89 6 672 678 2-s2.0-0037086184 10.1016/S0002-9149(01)02338-4 (Pubitemid 34230562)
183. Morgan J. M., Capuzzi D. M., Baksh R. I., Intenzo C., Carey C. M., Reese D., Walker K., Effects of extended-release Niacin on lipoprotein subclass distribution. The American Journal of Cardiology 2003 91 12 1432 1436 2-s2.0-0038201868 10.1016/S0002-9149(03)00394-1 (Pubitemid 36694719)
184. Hunninghake D. B., McGovern M. E., Koren M., Brazg R., Murdock D., Weiss S., Pearson T., A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clinical Cardiology 2003 26 3 112 118 2-s2.0-0037343026 (Pubitemid 36330859)
185. Mills E., Prousky J., Raskin G., Gagnier J., Rachlis B., Montori V. M., Juurlink D., The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTNI8054903]. BMC Clinical Pharmacology 2003 3, article 4 2-s2.0-2942545910 10.1186/1472-6904-3-4 (Pubitemid 38751345)
186. Grundy S. M., Vega G. L., McGovern M. E., Tulloch B. R., Kendall D. M., Fitz-Patrick D., Ganda O. P., Rosenson R. S., Buse J. B., Robertson D. D., Sheehan J. P., Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Archives of Internal Medicine 2002 162 14 1568 1576 2-s2.0-0037158150 10.1001/archinte.162.14.1568 (Pubitemid 34765005)
187. Leaf D. A., Connor W. E., Illingworth D. R., Bacon S. P., Sexton G., The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. Journal of the American Medical Association 1989 262 22 3154 3160 2-s2.0-0024355598 10.1001/jama.262.22.3154 (Pubitemid 20002634)
188. Steiner G., Fibrates in the metabolic syndrome and in the diabetes. Endocrinology and Metabolism Clinics of North America 2004 33 3 545 556 10.1016/j.ecl.2004.04.002 (Pubitemid 38953888)
189. Streja D., Combination therapy for the treatment of dyslipidemia. Current Opinion in Investigational Drugs 2004 5 3 306 312 2-s2.0-3042675771
190. Vega G. L., Ma P. T. S., Cater N. B., Filipchuk N., Meguro S., Garcia-Garcia A. B., Grundy S. M., Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. The American Journal of Cardiology 2003 91 8 956 960 2-s2.0-0037446467 10.1016/S0002-9149(03)00111-5 (Pubitemid 36398528)
191. Wierzbicki A. S., Mikhailidis D. P., Wray R., Schachter M., Cramb R., Simpson W. G., Byrne C. B., Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion 2003 19 3 155 168 2-s2.0-0013301537 10.1185/030079903125001668 (Pubitemid 36612998)
192. Turley S. D., Dietschy J. M., The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Preventive Cardiology 2003 6 1 29 64 2-s2.0-0037413223
193. Dujovne C. A., Ettinger M. P., McNeer J. F., Lipka L. J., LeBeaut A. P., Suresh R., Yang B. O., Veltri E. P., Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. The American Journal of Cardiology 2002 90 10 1092 1097 2-s2.0-0037111924 10.1016/S0002-9149(02)02798-4 (Pubitemid 35335597)
194. Mikhailidis D. P., Sibbring G. C., Ballantyne C. M., Davies G. M., Catapano A. L., Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion 2007 23 8 2009 2026 2-s2.0-34548125027 10.1185/030079907X210507 (Pubitemid 47300401)
195. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association 1984 251 3 365 374 10.1001/jama.1984.03340270043026
196. Engeli S., Böhnke J., Gorzelniak K., Janke J., Schling P., Bader M., Luft F. C., Sharma A. M., Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005 45 3 356 362 2-s2.0-14644395574 10.1161/01.HYP. 0000154361.47683.d3 (Pubitemid 40315803)
197. Whelton P. K., He J., Appel L. J., Cutler J. A., Havas S., Kotchen T. A., Roccella E. J., Stout R., Vallbona C., Winston M. C., Karimbakas J., Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. Journal of the American Medical Association 2002 288 15 1882 1888 2-s2.0-0037120907 (Pubitemid 35168144)
198. Israili Z. H., Lyoussi B., Hernández-Hernández R., Velasco M., Metabolic syndrome: treatment of hypertensive patients. The American Journal of Therapeutics 2007 14 4 386 402 2-s2.0-34547820945 10.1097/01.pap.0000249936. 05650.0c (Pubitemid 47224822)
199. Ball S. G., White W. B., Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers-a gap in evidence-based medicine. The American Journal of Cardiology 2003 91 10 15G 21G 2-s2.0-0038439326 10.1016/S0002-9149(03)00228-5 (Pubitemid 36638517)
200. Barnett A. H., Bain S. C., Bouter P., Karlberg B., Madsbad S., Jervell J., Mustonen J., Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. The New England Journal of Medicine 2004 351 19 1952 1961 2-s2.0-7444237666 10.1056/NEJMoa042274 (Pubitemid 39447136)
201. Abuissa H., Jones P. G., Marso S. P., O'Keefe J. H. Jr., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology 2005 46 5 821 826 2-s2.0-24044536393 10.1016/j.jacc.2005.05.051 (Pubitemid 41224805)
202. Bosch J., Yusuf S., Gerstein H. C., Pogue J., Sheridan P., Dagenais G., Chiasson J. L., Diaz R., Avezum A., Lanas F., Probstfield J., Fodor G., Holman R. R., Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine 2006 355 15 1551 1562 2-s2.0-33749590988 10.1056/NEJMoa065061 (Pubitemid 44550032)
203. Mancia G., Grassi G., Zanchetti A., New-onset diabetes and antihypertensive drugs. Journal of Hypertension 2006 24 1 3 10 2-s2.0-29244436688 (Pubitemid 41819128)
204. Pasternak R. C., The ALLHAT lipid lowering trial-less is less. Journal of the American Medical Association 2002 288 23 3042 3044 2-s2.0-0037132634 10.1001/jama.288.23.3042 (Pubitemid 35471168)
205. Black H. R., Davis B., Barzilay J., Nwachuku C., Baimbridge C., Marginean H., Wright J. T. Jr., Basile J., Wong N. D., Whelton P., Dart R. A., Thadani U., Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Diabetes Care 2008 31 2 353 360 2-s2.0-38949084591 10.2337/dc07-1452 (Pubitemid 351213350)
206. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2002 288 23 2981 2997
207. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L. Jr., Jones D. W., Materson B. J., Oparil S., Wright J. T. Jr., Roccella E. J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
208. Knowler W. C., Hamman R. F., Edelstein S. L., Barrett-Connor E., Ehrmann D. A., Walker E. A., Fowler S. E., Nathan D. M., Kahn S. E., Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 54 4 1150 1156 2-s2.0-15944395414 10.2337/diabetes.54.4.1150 (Pubitemid 40446330)
209. Chiasson J.-L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet 2002 359 9323 2072 2077 2-s2.0-0037097039 10.1016/S0140-6736(02)08905-5 (Pubitemid 34680970)
210. Orchard T. J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., Fowler S., The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Annals of Internal Medicine 2005 142 8 611 619 2-s2.0-17144389303 (Pubitemid 40529957)
211. Ratner R., Goldberg R., Haffner S., Marcovina S., Orchard T., Fowler S., Temprosa M., Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005 28 4 888 894 2-s2.0-15944424370 10.2337/diacare.28.4.888 (Pubitemid 40434491)
212. Molitch M. E., Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003 26 4 977 980 2-s2.0-0042168646 10.2337/diacare.26.4.977 (Pubitemid 36929234)
213. Chiasson J.-L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Journal of the American Medical Association 2003 290 4 486 494 2-s2.0-0038455703 10.1001/jama.290.4.486 (Pubitemid 37430502)
214. Rajagopalan R., Iyer S., Khan M., Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Current Medical Research and Opinion 2005 21 1 163 172 2-s2.0-14744278048 10.1185/030079904X20295 (Pubitemid 40327518)
215. Pearson T. A., Mensah G. A., Alexander R. W., Anderson J. L., Cannon R. O. III, Criqui M., Fadl Y. Y., Fortmann S. P., Hong Y., Myers G. L., Rifai N., Smith S. C. Jr., Taubert K., Tracy R. P., Vinicor F., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003 107 3 499 511 2-s2.0-0037469232 10.1161/01.CIR.0000052939.59093.45 (Pubitemid 36158056)
216. Schieffer B., Bünte C., Witte J., Hoeper K., Böger R. H., Schwedhelm E., Drexler H., Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. Journal of the American College of Cardiology 2004 44 2 362 368 2-s2.0-3242720779 10.1016/j.jacc.2004. 03.065 (Pubitemid 38960662)
217. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M. Jr., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
218. Shields T. M., Hennekens C. H., Management of metabolic syndrome: aspirin. Endocrinology and Metabolism Clinics of North America 2004 33 3 577 593 2-s2.0-3242728319 10.1016/j.ecl.2004.03.015 (Pubitemid 38953890)
219. Hennekens C. H., Dyken M. L., Fuster V., Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American heart association. Circulation 1997 96 8 2751 2753 2-s2.0-0030773146 (Pubitemid 27451385)
220. Blaha M. J., Bansal S., Rouf R., Golden S. H., Blumenthal R. S., DeFilippis A. P., A practical "ABCDE" approach to the metabolic syndrome. Mayo Clinic Proceedings 2008 83 8 932 943 2-s2.0-49249100260 10.4065/83.8.932
221. Eidelman R. S., Hebert P. R., Weisman S. M., Hennekens C. H., An update on aspirin in the primary prevention of cardiovascular disease. Archives of Internal Medicine 2003 163 17 2006 2010 2-s2.0-0141478649 10.1001/archinte.163. 17.2006 (Pubitemid 37151241)